Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02330380 · ClinicalTrials.gov registry record
Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
A clinical trial, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- 26
- Enrollment target
NCT02330380: Completed study, sponsored by University Hospitals Cleveland Medical Center.
NCT02330380 is a clinical trial that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02330380 has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
This is a prospective longitudinal observational pilot study of psoriasis patients on continuous standard-of-care systemic therapeutics to determine the level of change in established (plasma/serum) and investigative (cellular) biomarkers that are associated with increased risk of CVD events. The final endpoint of the proposed study will be a ranking of the examined biomarkers based upon an integrated assessment of biomarker behavior over time. Secondary outcomes will assess changes in coronary artery calcification scoring, PET-MRI, skin biopsies, and clinical improvement.
Primary Outcome
The biomarkers examined throughout the study will be assessed. And, an integrated assessment of biomarker behavior over time will be performed. Biomarkers examined will include High sensitivity C-reactive protein (hsCRP), Myeloperoxidase (MPO), resistin, adiponectin and leptin.
Interventions
- DRUG Ustekinumab
- DRUG Adalimumab
- DRUG Methotrexate
- DRUG Etanercept
- DRUG Acitretin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-04 |
| Est. Completion | 2016-12 |
What the finished NCT02330380 record still lists
NCT02330380 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which Ustekinumab is the first listed.
NCT02330380 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02330380 about?
NCT02330380 is a clinical study titled "Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation". This is a prospective longitudinal observational pilot study of psoriasis patients on continuous standard-of-care systemic therapeutics to determine the level of change in established (plasma/serum) and investigative (cellular) biomarkers that are associated with increased risk of CVD events. The f...
What is the current status of trial NCT02330380?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2013-04. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02330380?
The interventions under investigation include: Ustekinumab (DRUG), Adalimumab (DRUG), Methotrexate (DRUG), Etanercept (DRUG), Acitretin (DRUG).
Who is sponsoring clinical trial NCT02330380?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia